Logo

American Heart Association

  23
  0


Final ID:

Aldosterone synthase inhibitors – a potentially new class of antihypertensive drugs

  • Laffin, Luke  ( Cleveland Clinic Foundation , Cleveland , Ohio , United States )
  • Luther, James  ( VANDERBILT UNIV MED CTR , Nashville , Tennessee , United States )
  • Kline, Gregory  ( University of Calgary , Calgary , Alberta , Canada )
  • Author Disclosures:
    Luke Laffin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Mineralys:Active (exists now) ; Consultant:Ripple Medical:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Recor:Active (exists now) ; Royalties/Patent Beneficiary:Elsevier:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Crispr Theapeutics:Active (exists now) ; Research Funding (PI or named investigator):Kardigan:Active (exists now) ; Consultant:Astrazeneca:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now) | James Luther: DO have relevant financial relationships ; Consultant:Mineralys:Active (exists now) ; Other (please indicate in the box next to the company name):AHA (editorial board):Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) | Gregory Kline: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
The wide spectrum of primary aldosteronism

Vaidya Anand, Hundemer Gregory, Adler Gail

‘Primarily Aldosteronism’: from genetic diversity to resisting Hypertension

Brown Morris, Williams Tracy, Zennaro Maria-christina

You have to be authorized to contact abstract author. Please, Login
Not Available